

Department: UAMS Institutional Review Board
Policy Number: 17.8
Section: Special Populations
Effective Date: July 31, 2002
Revision Date: July 9, 2004; March 13, 2008

SUBJECT: Pregnant Women, Human Fetuses and Neonates Involved in Research

This policy applies to all research, development, and related activities involving: (1) pregnant women, (2) human fetuses, and (3) neonates and is based on the federal regulations at 45 CFR 46 Subpart B. The requirements in this Policy are in addition to those imposed under the other IRB policies and other applicable federal, state and local laws.

Research involving women who are or may become pregnant will receive special attention from the IRB because of women's additional health concerns during pregnancy and because of the need to avoid unnecessary risk to the fetus. Further, in the case of a pregnant woman, the UAMS IRB will determine when the informed consent of the father to the research is required. Special attention is justified because of the involvement of a third party (the fetus) who may be affected but cannot give consent and because of the need to prevent harm or injury to the fetus. Procedural protections beyond the basic requirements for protecting human subjects are prescribed in federal regulations for research involving pregnant women.

Definitions

"Dead fetus" means a fetus that exhibits neither heartbeat, spontaneous respiratory activity, spontaneous movement of voluntary muscles, nor pulsation of the umbilical cord.

"Delivery" means complete separation of the fetus from the woman by expulsion or extraction or any other means.

"Fetus" means the product of conception from implantation until delivery.

"Neonate" means a newborn.

"Nonviable neonate" means a neonate after delivery that, although living, is not viable.

"Pregnancy" encompasses the period of time from implantation until delivery. A woman shall be assumed to be pregnant if she exhibits any of the pertinent presumptive signs of pregnancy, such as missed menses, until the results of a pregnancy test are negative or until delivery.

"Secretary" means the Secretary of Health and Human Services and any other officer or employee of the Department of Health and Human Services to whom authority has been delegated.

"Viable" as it pertains to the neonate means being able, after delivery, to survive (given the benefit of available medical therapy) to the point of independently maintaining heartbeat and respiration. The Secretary may from time to time, taking into account medical advances, publish in the Federal Register guidelines to assist in determining whether a neonate is viable for purposes of this subpart. If a neonate is viable then it may be included in research only to the extent permitted in 45 CFR 56 Subparts A and D.

Procedure: Investigators submitting studies which fall under this policy should design their protocols, consents and processes with these additional requirements in mind in addition to the standard requirements for human research. The IRB must find and document that the applicable conditions below are met.

Additional Requirements For All Studies Covered by the Policy

In addition to other responsibilities assigned to the IRB under this policy, the IRB shall review research covered by this policy and applicable regulations and approve only research which satisfies the conditions of all applicable sections of this policy, 45 CFR 46 Subpart B, and the other applicable subparts of 45 CFR 46.

In addition to all other requirements for approval, the UAMS IRB will determine that:

1. Adequate consideration has been given to the manner in which potential subjects will be selected; and

2. Adequate provision has been made by the investigator for monitoring the actual informed consent process (e.g., through such mechanisms, when appropriate, as participation by the IRB or subject advocates in (i) overseeing the actual process by which individual consents are secured either by approving induction of each individual into the activity or verifying, perhaps through sampling, that approved procedures for induction of individuals into the activity are being followed, and (ii) monitoring the progress of the activity and intervening as necessary through such steps as visits to the activity site and continuing evaluation to determine if any unanticipated risks have arisen).
3. No person on the research team will play any role in the determination of fetal viability.

Research Involving Pregnant Women or Fetuses

Pregnant women or fetuses may be involved in research if all of the following conditions are met. The UAMS IRB will determine whether these conditions are met and will document its determination:

- (a) Where scientifically appropriate, preclinical studies, including studies on pregnant animals, and clinical studies, including studies on nonpregnant women, have been conducted and provide data for assessing potential risks to pregnant women and fetuses;
- (b) The risk to the fetus is caused solely by interventions or procedures that hold out the prospect of direct benefit for the woman or the fetus; or, if there is no such prospect of benefit, the risk to the fetus is not greater than minimal and the purpose of the research is the development of important biomedical knowledge which cannot be obtained by any other means;
- (c) Any risk is the least possible for achieving the objectives of the research;
- (d) If the research holds out the prospect of direct benefit to the pregnant woman, the prospect of a direct benefit both to the pregnant woman and the fetus, or no prospect of benefit for the woman nor the fetus when risk to the fetus is not greater than minimal and the purpose of the research is the development of important biomedical knowledge that cannot be obtained by any other means, her consent is obtained in accord with the informed consent provisions of 45 CFR 46 Subpart A of this part and relevant IRB policies pertaining to informed consent.
- (e) If the research holds out the prospect of direct benefit solely to the fetus then the consent of the pregnant woman and the father is obtained in accord with the informed consent provisions of 45 CFR 46 Subpart A and relevant IRB policies pertaining to informed consent, except that the father's consent need not be obtained if he is unable to consent because of unavailability, incompetence, or temporary incapacity or the pregnancy resulted from rape or incest.
- (f) Each individual providing consent under paragraph (d) or (e) above is fully informed regarding the reasonably foreseeable impact of the research on the fetus or neonate;
- (g) For children as defined in 45 CFR 46.402(a) who are pregnant, assent and permission are obtained in accord with the provisions of 45 CFR 46 Subpart D and relevant IRB policies pertaining to research involving children;
- (h) No inducements, monetary or otherwise, will be offered to terminate a pregnancy;
- (i) Individuals engaged in the research will have no part in any decisions as to the timing, method, or procedures used to terminate a pregnancy; and
- (j) Individuals engaged in the research will have no part in determining the viability of a neonate.

Research involving neonates

- (a) Neonates of uncertain viability and nonviable neonates may be involved in research if all of the following conditions are met:
 - (1) Where scientifically appropriate, preclinical and clinical studies have been conducted and provide data for assessing potential risks to neonates.
 - (2) Each individual providing consent under paragraph (b)(2) or (c)(5) of this section is fully informed regarding the reasonably foreseeable impact of the research on the neonate.
 - (3) Individuals engaged in the research will have no part in determining the viability of a neonate.
 - (4) The requirements of paragraph (b) or (c) of this section have been met as applicable.
- (b) Neonates of uncertain viability. Until it has been ascertained whether or not a neonate is viable, a neonate may not be involved in research covered by this subpart unless the following additional conditions have been met:
 - (1) The IRB determines that:
 - (i) The research holds out the prospect of enhancing the probability of survival of the neonate to the point of viability, and any risk is the least possible for achieving that objective, or

(ii) The purpose of the research is the development of important biomedical knowledge which cannot be obtained by other means and there will be no added risk to the neonate resulting from the research; and

(2) The legally effective informed consent of either parent of the neonate or, if neither parent is able to consent because of unavailability, incompetence, or temporary incapacity, the legally effective informed consent of either parent's legally authorized representative is obtained in accord with 45 CFR 46 Subpart A, except that the consent of the father or his legally authorized representative need not be obtained if the pregnancy resulted from rape or incest.

(c) Nonviable neonates. After delivery nonviable neonate may not be involved in research covered by this subpart unless all of the following additional conditions are met:

(1) Vital functions of the neonate will not be artificially maintained;

(2) The research will not terminate the heartbeat or respiration of the neonate;

(3) There will be no added risk to the neonate resulting from the research;

(4) The purpose of the research is the development of important biomedical knowledge that cannot be obtained by other means; and

(5) The legally effective informed consent of both parents of the neonate is obtained in accord with 45 CFR 46 Subpart A except that the waiver and alteration provisions of 45 CFR 46.116(c) and (d) and UAMS IRB Policy 15.3 do not apply. However, if either parent is unable to consent because of unavailability, incompetence, or temporary incapacity, the informed consent of one parent of a nonviable neonate will suffice to meet the requirements of this paragraph (c)(5), except that the consent of the father need not be obtained if the pregnancy resulted from rape or incest. The consent of a legally authorized representative of either or both of the parents of a nonviable neonate will not suffice to meet the requirements of this paragraph (c)(5).

(d) Viable neonates. A neonate, after delivery, that has been determined to be viable may be included in research only to the extent permitted by and in accord with the requirements of 45 CFR 46 Subparts A and D.

Research Involving, after delivery, the Dead Fetus, Fetal Material, or the Placenta.

(a) Research involving, after delivery, the placenta; the dead fetus; macerated fetal material; or cells, tissue, or organs excised from a dead fetus shall be conducted only in accord with any applicable federal, state or local laws regarding such activities.

(b) If information associated with material described in paragraph (a) of this section is recorded for research purposes in a manner that living individuals can be identified, directly or through identifiers linked to those individuals, those individuals are research subjects and all pertinent subparts of this part are applicable.

Research not otherwise approvable which presents an opportunity to understand, prevent, or alleviate a serious problem affecting the health and welfare of pregnant women, fetuses, or neonates

The Secretary will conduct or fund, and the IRB will consider for approval, research that the IRB does not believe meets the requirements of 45 CFR 46.204 (Research Involving Pregnant Women or Fetuses) or 45 CFR 46.205 (Research Involving Neonates) only if:

(a) The IRB finds that the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of pregnant women, fetuses, or neonates; and

(b) The Secretary, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, ethics, law) and following opportunity for public review and comment, including a public meeting announced in the Federal Register, has determined either:

(1) That the research in fact satisfies the conditions of 45 CFR 46.204, as applicable; or

(2) The following:

(i) The research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of pregnant women, fetuses, or neonates;

(ii) The research will be conducted in accord with sound ethical principles; and

(iii) Informed consent will be obtained in accord with the informed consent provisions of 45 CFR 46 Subpart A and other applicable subparts.

Other Studies . Federal regulations require that, when appropriate, subjects be provided a statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable as part of the informed consent process.

The IRB must judge whether a pregnant or nursing woman's participation would pose any risk to the fetus or nursing infant. In some studies, the IRB may need to ensure that non-pregnant subjects are advised to avoid pregnancy or nursing for a time during or following the research. Furthermore, where appropriate, subjects should be advised to notify the investigator immediately should they become pregnant. In some instances, there may be potential risk sufficient to justify requiring that pregnant women either be specifically excluded from the research or studied separately.